Section 5 of 6
Economic information and modeling report
15 evidence topics · 15 sources
Modeling overview
Summary
No source in this report presents a cost-effectiveness or budget impact model of COMP360 itself, and none quotes a price for it. ICER is assessing synthetic psilocybin against esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation, with a model analysis plan due January 22, 2027, a five-year health care system cost-effectiveness model, and a separate five-year budget impact analysis; its final evidence report is scheduled for 06/21/2027. Published analyses of psilocybin therapy report $117,517 per QALY gained over 12 months from a limited healthcare perspective, cost savings of approximately $7000 per patient compared with standard of care, and cost-effectiveness when the cost of therapist support was reduced by 50% and the psilocybin price to £400 to £800 per person. For the comparator, ICER's 2019 report estimated approximately $198,000 per QALY gained for esketamine. The company plans drug reimbursement through the pharmacy benefit and monitoring through CPT Category III codes, and presented health economics posters on real-world costs across TRD health states at Psych Congress 2026. A payer panel noted that the effect of psilocybin on later treatment needs leaves “an uncertain impact to the total cost of care.”
ICER assessment of synthetic psilocybin: announcement and timeline
“11/18/2026 Revised Scoping Document” (opens the source at this quote in a new tab)
“01/22/2027 Model Analysis Plan” (opens the source at this quote in a new tab)
“03/16/2027 Draft Evidence Report” (opens the source at this quote in a new tab)
“05/20/2027 Evidence Presentation” (opens the source at this quote in a new tab)
“06/21/2027 Final Evidence Report and Meeting Summary” (opens the source at this quote in a new tab)
ICER planned cost-effectiveness analysis
ICER planned budget impact analysis
Published cost-effectiveness analysis: United States, psilocybin-assisted therapy as third-line treatment
“We assumed the total cost of PAT was $5000, which we varied in sensitivity analyses ($3000–20,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAT leads to an additional 0.031 QALYs and $3639 costs compared to SOC over 12 months, giving an ICER of $117,517 per QALY gained from a limited healthcare perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a $150,000 cost-effectiveness threshold, PAT had a 75% probability of being the cost-effective choice, and it was associated with a lower expected loss than SOC ($301 vs. $1307).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAT had a 1% probability of being cost-effective when its overall costs were $10,000 and 95% when its costs were $3000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-effectiveness analysis: United States Markov model with a 6-week cycle
“Compared with the standard of care, PAT was more effective and less costly, yielding approximately $7000 in cost savings and a gain of 0.10 QALYs per patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Extending the horizon to 30 years in scenario analyses increased cumulative savings to $215 900 with gains of 9.87 QALYs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-effectiveness analysis: United Kingdom, 6-month decision model
“The expected healthcare cost of PAP varied from £6132 to £7652 depending on the price of psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QALYs were highest for psilocybin (0.310), followed by CBT alone (0.283), conventional medication alone (0.278), and their combination (0.287).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin was shown to be cost-effective compared to the other therapies when the cost of therapist support was reduced by 50% and the psilocybin price was reduced from its initial value to £400 to £800 per person.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinician costs with group compared with individual monitoring
Comparator context: ICER 2019 evaluation of esketamine
Comparator context: published United States cost-effectiveness analysis of esketamine
“Base case ICERs were $237,111/QALY (societal) and $242,496/QALY (healthcare sector).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At a cost-effectiveness threshold of $150,000/QALY, esketamine’s value-based price was approximately $140/dose (versus a current price of $240/dose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statements on pricing and value
Company reimbursement model: drug through the pharmacy benefit, monitoring through the medical benefit
Payer panel: cost and total cost of care concerns
“Additionally, payer participants are concerned with the cost-effectiveness of potentially requiring multiple health professionals at specialized centers to provide psilocybin administration and observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, payer participants emphasized that the unknown impact of psilocybin on ongoing treatment needs results in an uncertain impact to the total cost of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company health economics and outcomes research posters at Psych Congress 2026
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.